SEC Comment Letter for Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — May 18, 2018
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: May 18, 2018 · CIK: 0001213037 · Accession: 0000000000-18-015445
AI Filing Summary & Sentiment
File numbers found in text: 333-224808
Letter
May 18, 2018 William Welch Chief Executive Officer Trovagene, Inc. 11055 Flintkote Avenue San Diego, CA 92121 Re:Trovagene, Inc. Registration Statement on Form S-1 Filed May 10, 2018 File No. 333-224808 Dear Mr. Welch: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Jeffrey Fessler
Show Raw Text
May 18, 2018
William Welch
Chief Executive Officer
Trovagene, Inc.
11055 Flintkote Avenue
San Diego, CA 92121
Re:Trovagene, Inc.
Registration Statement on Form S-1
Filed May 10, 2018
File No. 333-224808
Dear Mr. Welch:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Jeffrey Fessler